Raymond James Financial Inc. Acquires New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Raymond James Financial Inc. acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 456,774 shares of the biopharmaceutical company's stock, valued at approximately $21,838,000. Raymond James Financial Inc. owned approximately 0.36% of Halozyme Therapeutics at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Janney Montgomery Scott LLC raised its holdings in shares of Halozyme Therapeutics by 698.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock worth $13,756,000 after acquiring an additional 251,711 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Halozyme Therapeutics by 60.0% in the fourth quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company's stock worth $31,112,000 after acquiring an additional 243,940 shares during the period. Boston Trust Walden Corp lifted its holdings in shares of Halozyme Therapeutics by 28.0% during the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company's stock valued at $41,790,000 after purchasing an additional 191,465 shares during the last quarter. South Street Advisors LLC purchased a new stake in Halozyme Therapeutics in the third quarter valued at about $9,812,000. Finally, Hantz Financial Services Inc. purchased a new stake in shares of Halozyme Therapeutics during the third quarter worth about $9,260,000. 97.79% of the stock is currently owned by institutional investors.

Remove Ads

Halozyme Therapeutics Price Performance

HALO stock traded up $1.79 during midday trading on Wednesday, reaching $64.33. The stock had a trading volume of 990,371 shares, compared to its average volume of 1,311,085. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The company's fifty day simple moving average is $57.53 and its 200 day simple moving average is $54.61. The company has a market cap of $7.92 billion, a price-to-earnings ratio of 18.76, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on HALO. Piper Sandler lifted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Benchmark reiterated a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Wells Fargo & Company dropped their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company's stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the sale, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.